Millie
your market intelligence analyst
Search Results
658 results
Your search is now limited to «Prostate Cancer» expert search.
KeeWI There is a good booklet produced by Macmillan called "Having tests for prostate cancer" which gives details of all the tests, what they mean and explains staging. You can download it from this web page as a pdf https://be.macmillan.org.uk/be/s-671-cancer-type-p.aspx As I suggested before you could also contact or call in at a Macmillan Information and Support Centre if you just want someone to talk to about your worries. They could also signpost you to any other local cancer charity who may also have the facility to talk to someone and/or a support group. Support groups are where people with the same cancer get together share their experiences and support each other. The link for locating a MISC is https://www.macmillan.org.uk/in-your.
More from Macmillan Cancer - Prostate Forum:
PubMed News (NIH) 07/20/2019
Contributors : Ayse D Cavga ; Nathan A Lack Series Type : Expression profiling by high throughput sequencing Organism : Homo sapiens. Prostate cancer is a leading cause of cancer related death among men. Current Androgen Receptor (AR) antagonists often target the ligand binding domain (LBD). However, occurrence of resistance to drugs targeting the LBD is common due to emergence of mutations in the LBD or constitutively active variants that lack the LBD itself. Two novel small molecules, VPC-17005 and VPC-14449 targeting the DNA-binding domain have been developed and published previously. In this study, LNCaP cells were treated with one of these drugs or the well-established AR antagonist Enzalutamide, and the transcriptomic changes have been.
More from PubMed News (NIH):
Business Wire 07/19/2019 18:19
BEERSE, Belgique--(BUSINESS WIRE)--Les sociétés pharmaceutiques Janssen de Johnson & Johnson se réjouissent de la récente décision de l'Organisation mondiale de la santé (OMS) d'inclure l'acétate d'abiratérone (ZYTIGA®) pour le traitement du cancer de la prostate résistant à la castration métastatique (CPRCm), dans la liste mise à jour des médicaments essentiels, publiée le 9 juillet 2019.1,2 La liste de l'OMS est un document fondamental aidant les pays à classer les principaux produits de.
More from Business Wire:
News-Medical.net 07/19/2019 10:12
The Janssen Pharmaceutical Companies of Johnson & Johnson is delighted with the recent announcement from the World Health Organisation (WHO) to include abiraterone acetate (ZYTIGA®) for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
More from News-Medical.net:
ClinicalTrials.gov 07/19/2019 06:55
Secondary objectives include exploring whether atorvastatin lowers prostate cancer-specific or overall mortality compared to placebo, and to demonstrate whether changes in serum lipid parameters predict disease recurrence and occurrence of adverse genomic changes predicting castration resistance among prostate cancer patients during ADT.
More from ClinicalTrials.gov:
PharmiWeb.com 07/18/2019 22:03
Diagnosis of prostate cancer has, until now, been lagging behind other cancers and we believe that with the launch and subsequent further use of this test, that will no longer be the case.
More from PharmiWeb.com:
BIOENGINEER.ORG 07/18/2019 16:01
Study reports pre-clinical development of novel treatment and potential for combination use with immunotherapy drugs Researchers at The University of Texas MD Anderson Cancer Center have discovered how an aggressive form of prostate cancer called double-negative prostate cancer (DNPC) metastasizes by evading the immune system.
More from BIOENGINEER.ORG:
Healio News 07/18/2019 14:56
Elderly men with prostate cancer appeared more likely to be diagnosed with Alzheimer’s disease or dementia if treated with androgen deprivation therapy, according to study results published in JAMA Network Open.
More from Healio News:
BioNewsFeeds 07/18/2019 12:33
The current gold standard for diagnosing and assessing risk in prostate cancer is a biopsy — inserting a needle into the prostate and taking cells for examination.
More from BioNewsFeeds:
ecancer news 07/18/2019 12:00
Discovery shows how difficult-to-treat prostate cancer evades immune system.
More from ecancer news:
This draft guidance describes the FDA's current recommendations regarding the overall development program and clinical trial designs for developing gonadotropin-releasing hormone (GnRH) analogues to treat advanced prostate cancer.
More from Federal Register - Public Inspection (OFR):
Fatigue was measured using the revised Piper Fatigue Scale from 52 patients with prostate cancer.
More from International Journal of COPD:
Since the introduction of PSA testing, significantly more men have been diagnosed and treated for prostate cancer.
More from RSC - Chem Sci Latest Articles:
Cancer can be an isolating experience. No two cases are the same, but Rodney Hardcastle’s own experience has inspired him to craft an essay exploring the ways in which the cancer is synonymous with terrorism on the body. .
More from ZERO – The End of Prostate Cancer:
Prostate Cancer INFOLINK 07/17/2019 09:18
The fully adjusted predicted proportions of advanced prostate cancer diagnosis across 158 counties ranged from 3% to 15.
More from Prostate Cancer INFOLINK:
Researchers in the Perelman School of Medicine at the University of Pennsylvania and the Roberts Proton Therapy Center examined data on non-metastatic prostate cancer patients treated with 28 doses of proton therapy instead of the standard 44.
More from Imaging Technology News:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors

Cells

Diagnostics and Therapeutics

Diseases

Drugs - Brand Names

Drugs - Generic

Enzymes

Genes

Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices

Proteins

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications